Severe forms of neurocysticercosis: Treatment with albeimdazole

Página do item simplificado
dc.contributor.authorAgapejev, Svetlana [UNESP]
dc.contributor.authorDa Silva, Maria Dorvalina
dc.contributor.authorUeda, Anete K.
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:18:04Z
dc.date.available2014-05-27T11:18:04Z
dc.date.issued1996-03-01
dc.description.abstractStudy of 22 patients with the severe form of neurocysticercosis treated with albendazole (ABZ) administered in 6 different schedules ranging from 15 to 30 mg/kg/day for 21 to 60 days. Dextrochloropheniramine and ketoprofen were the adjuvant drugs Multiple symptoms were observed in 90 9% of patients. Intracranial hypertension was manifested in 90.9%. Hydrocephaly occurred in 86.4%. Evolution was satisfactory in 10 patients, 8 died and 4 had sequelae. Tomographic studies showed the appearance of an isolated IVth ventricle in 9 patients, after ventriculoperitoneal shunt, before ABZ treatment in 3 of them, during in 5 and after treatment in one. Median clinical follow-up duration was 10 months for the patients who died and 3-4 years for survivors. In 3 patients there was an increase in cyst size during the administration of the 15 mg/kg/day ABZ dose, which was not observed in any patient when the 30 mg/kg/day dose was used.en
dc.description.affiliationDivision of Neurology Botucatu School of Medicine State University of São Paulo
dc.description.affiliationDept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP
dc.description.affiliationUnespDept. of Neurology and Psychiatry School of Medicine UNESP, P.O Box 540, 18618-000 Botucatu SP
dc.format.extent82-93
dc.identifierhttp://dx.doi.org/10.1590/S0004-282X1996000100014
dc.identifier.citationArquivos de Neuro-Psiquiatria, v. 54, n. 1, p. 82-93, 1996.
dc.identifier.doi10.1590/S0004-282X1996000100014
dc.identifier.file2-s2.0-0029965675.pdf
dc.identifier.issn0004-282X
dc.identifier.scieloS0004-282X1996000100014
dc.identifier.scopus2-s2.0-0029965675
dc.identifier.urihttp://hdl.handle.net/11449/64750
dc.identifier.wosWOS:A1996TZ93500014
dc.language.isoeng
dc.relation.ispartofArquivos de Neuro-Psiquiatria
dc.relation.ispartofjcr1.015
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectAlbendazole
dc.subjectCysticercosis
dc.subjectDextrochloropheniramine
dc.subjectKetoprofen
dc.subjectNeurocysticercosis
dc.subjectSevere forms
dc.subjectTreatment
dc.subjectacetazolamide
dc.subjectalbendazole
dc.subjectdexchlorpheniramine
dc.subjectketoprofen
dc.subjectmannitol
dc.subjectadolescent
dc.subjectadult
dc.subjectclinical article
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectneurocysticercosis
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAnthelmintics
dc.subjectBrain Diseases
dc.subjectChlorpheniramine
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectTomography, X-Ray Computed
dc.titleSevere forms of neurocysticercosis: Treatment with albeimdazoleen
dc.typeArtigo
dcterms.licensehttp://www.scielo.br/revistas/anp/paboutj.htm
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
2-s2.0-0029965675.pdf
Tamanho:
1.44 MB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Neurologia, Psicologia e Psiquiatria - FMB